Analysts’ Viewpoint
Rise in prevalence of cardiovascular diseases is significantly driving the cardiotonic agents industry growth. High incidence of heart diseases and the presence of well-established healthcare infrastructure across several countries are contributing to the cardiotonic agents market development. Rise in number of cardiac surgeries across the globe and development of new medications for emergency and critical care situations are augmenting market growth.
Advancements in drug development are creating lucrative cardiotonic agents market opportunities for market participants. Manufacturers in the market are engaged in R&D activities to explore new types of cardiotonic agents. Development of medications, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which can improve heart function is fueling market statistics.
Cardiotonic agents, also known as inotropic agents, are medications that affect the heart's contractility and improve its function. These agents are commonly used in the treatment of heart failure, arrhythmias, and other cardiovascular conditions.
Digoxins are cardiotonic drugs that are used to increase the force of the heart's contractions and slow down the heart rate, thereby improving blood circulation. Digitalis glycosides have been used for decades and are still a common treatment option for heart failure, atrial fibrillation, and other cardiovascular conditions. However, their use has declined in the last few years due to the availability of newer medications with fewer side effects.
Another type of cardiotonic agent is beta-adrenergic agonists, such as dobutamine. These drugs stimulate the beta-receptors in the heart and increase the heart's contractility. Beta-adrenergic agonists are commonly utilized in the treatment of acute heart failure and shock, as they rapidly increase cardiac output and improve blood pressure. However, their use is limited due to their potential for adverse effects, such as tachycardia and arrhythmias.
Calcium sensitizers, such as levosimendan, are a newer class of cardiotonic agents that improve the heart's contractility by increasing its sensitivity to calcium. Calcium sensitizers are used in the treatment of heart failure and are particularly effective in patients with reduced ejection fraction.
Cardiovascular diseases (CVDs) are a major cause of morbidity and mortality worldwide, with heart failure being one of the most common cardiovascular conditions. The incidence of heart failure is expected to rise in the near future, owing to the rise in the geriatric population and the surge in the prevalence of obesity, diabetes, and high blood pressure. This has led to an increased demand for cardiotonic agents to manage the condition. Several new medications are being developed to reduce the risk of cardiovascular death.
According to a report by the American Heart Association, heart failure affects nearly 6.2 million adults in the U.S., and it is projected to increase by 46.0% by 2030. The rise in the prevalence of heart failure is driving the demand for cardiotonic agents such as digoxin and milrinone, which are commonly used to improve cardiac function in patients with heart failure.
Technological advancements in the development of cardiotonic agents are driving market progress. New drugs are being developed with improved efficacy and safety profiles. Novartis developed Entresto, a combination drug that has been shown to be effective in reducing cardiovascular death and hospitalization for heart failure.
In addition to the development of new drugs, companies are also investing in the development of advanced drug delivery systems and novel formulations. For instance, Milestone Pharmaceuticals has developed a novel drug delivery system for etripamil, a drug used to treat certain types of cardiac arrhythmias. The delivery system allows for rapid administration of etripamil and has been shown to be effective in treating patients with supraventricular tachycardia.
Other companies are exploring the use of nanotechnology in the development of novel formulations for cardiotonic agents. Nanotechnology involves the manipulation of particles on a nanoscale level and has the potential to improve the efficacy and safety of drugs.
The phosphodiesterase inhibitors drug type segment dominated the global industry in 2022. This segment is likely to maintain its dominance during the forecast period. Growth of the phosphodiesterase inhibitors drug type segment is attributable to the increase in the prevalence of heart failure and other cardiovascular diseases, as well as the rise in demand for effective and safe treatments.
Sildenafil is a phosphodiesterase inhibitor that was originally developed as a treatment for erectile dysfunction; however, later, it was found to be effective for cardiovascular diseases. Studies have shown that sildenafil can improve exercise capacity and quality of life in patients with heart failure.
The cardiac surgical procedures application segment accounted for the largest share of the global market in 2022. The increase in demand for cardiac surgeries, such as bypass surgeries, valve replacements, and heart transplants, as well as the rise in the need for medications to support and enhance the outcomes of these surgeries, are driving the segment.
Dopamine is often used during cardiac surgery to increase blood pressure and improve cardiac output. Other medications commonly used in cardiac surgical procedures include nitroglycerin, which can dilate blood vessels and improve blood flow, and heparin, which is used to prevent blood clots during surgery.
Several pharmaceutical companies have been investing in the development of new cardiotonic agents to improve the outcomes of cardiac surgical procedures.
In terms of the route of administration, the global market has been divided into oral and parenteral. As per the latest cardiotonic agents market trends, the parenteral route of administration segment dominated in 2022. It is anticipated to lead the global market in the next few years.
Parenteral administration refers to the delivery of medication through injection or infusion directly into the bloodstream, bypassing the gastrointestinal tract. This route of administration is often used for cardiotonic agents in emergency and critical care situations, where rapid onset and precise dosing are crucial.
Common examples of parenteral cardiotonic agents include dobutamine, which is used to improve heart function in cases of acute heart failure. Other medications administered parenterally include epinephrine, norepinephrine, and nitroglycerin.
Several pharmaceutical companies have started investing in the development of new parenteral cardiotonic agents, including Novartis and its medication LCZ696, which has shown promising results in the treatment of heart failure.
According to the latest cardiotonic agents market analysis, the solution dosage form segment accounted for major share of the global industry in 2022. The solution dosage form segment is projected to lead the global market in the near future.
Cardiotonic agents can be delivered effectively using oral solutions, intravenous solutions, and others. Digoxin is given in a solution form, which is commonly used in the treatment of heart failure and certain arrhythmias. It is available in both oral and intravenous solution forms.
Based on distribution channels, the global industry has been divided into hospital pharmacies retail pharmacies, and online pharmacies. According to the latest cardiotonic agents industry research report, the hospital pharmacies distribution channel segment is expected to account for major share during the forecast period.
Hospital pharmacies are an important distribution channel for cardiotonic agents, as these medications are often administered in a hospital or clinical setting, and require specialized expertise for proper storage, handling, and administration.
Retail pharmacies are often used for the distribution of oral cardiotonic agents for outpatient use, while online pharmacies are becoming increasingly popular for the purchase and delivery of these medications.
As per the latest cardiotonic agents market forecast, North America held major share of the global landscape in 2022. It is projected to maintain its dominance during the forecast period. This can be attributed to high prevalence of cardiovascular diseases in the region, advanced healthcare infrastructure, and increase in healthcare spending.
The U.S. is the largest market for cardiotonic agents in North America, with several major pharmaceutical companies operating in the region. These companies include Pfizer Inc, Novartis, and Amgen. These companies are actively engaged in the development and commercialization of cardiotonic agents.
The cardiotonic agents market size in Asia Pacific is anticipated to increase in the near future. Rise in incidence of cardiovascular diseases and increase in demand for effective treatments are significant factors fueling cardiotonic agents market growth in the region.
The cardiotonic agents market demand is rising in Asia Pacific due to the rise in geriatric population in the region. The presence of several major pharmaceutical companies in Asia Pacific countries, such as Japan, China, and India, is fueling market expansion in the region.
Amneal Pharmaceuticals LLC, Pfizer Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi, Midas Pharma GmbH, Sanofi, Aurobindo Pharma Limited, and SimSon Pharma Limited are the major players operating in the global market. These players are engaged in mergers & acquisitions, strategic collaborations, and new product launches to strengthen their cardiotonic agents market share.
Key players have been profiled in the cardiotonic agents market report based on parameters such as business strategies, company overview, product portfolio, financial overview, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size in 2022 |
US$ 732.0 Mn |
|
Forecast (Value) in 2031 |
More than US$ 4.5 Bn |
|
Growth Rate (CAGR) |
21.3% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2022 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 732.0 Mn in 2022.
It is projected to reach more than US$ 4.5 Bn by 2031.
The CAGR is anticipated to be 21.3% from 2023 to 2031.
The cardiac surgical procedures application segment held major share in 2022.
North America is expected to account for major share during the forecast period.
Amneal Pharmaceuticals LLC, Pfizer Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi, Midas Pharma GmbH, Sanofi, Aurobindo Pharma Limited, and SimSon Pharma Limited.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiotonic Agents Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiotonic Agents Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events
5.2. Technological Advancements
5.3. Value Chain Analysis
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Cardiotonic Agents Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. Digitalis Glycosides
6.3.2. Phosphodiesterase Inhibitors
6.3.3. Cardioprotectants
6.3.4. Sympathomimetic Agents
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Cardiotonic Agents Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Cardiac Surgical Procedures
7.3.2. Atrial Fibrillation
7.3.3. Heart Failure
7.3.4. Pulmonary Hypertension
7.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
7.4. Market Attractiveness Analysis, by Application
8. Global Cardiotonic Agents Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Cardiotonic Agents Market Analysis and Forecast, by Dosage Form
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Dosage Form, 2017–2031
9.3.1. Tablet
9.3.2. Solution
9.3.3. Others
9.4. Market Attractiveness Analysis, by Dosage Form
10. Global Cardiotonic Agents Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Cardiotonic Agents Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Cardiotonic Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. Digitalis Glycosides
12.2.2. Phosphodiesterase Inhibitors
12.2.3. Cardioprotectants
12.2.4. Sympathomimetic Agents
12.2.5. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Cardiac Surgical Procedures
12.3.2. Atrial Fibrillation
12.3.3. Heart Failure
12.3.4. Pulmonary Hypertension
12.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Dosage Form, 2017–2031
12.5.1. Tablet
12.5.2. Solution
12.5.3. Others
12.6. Market Value Forecast, by Distribution Channel, 2017–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Application
12.8.3. By Route of Administration
12.8.4. By Dosage Form
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Cardiotonic Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. Digitalis Glycosides
13.2.2. Phosphodiesterase Inhibitors
13.2.3. Cardioprotectants
13.2.4. Sympathomimetic Agents
13.2.5. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Cardiac Surgical Procedures
13.3.2. Atrial Fibrillation
13.3.3. Heart Failure
13.3.4. Pulmonary Hypertension
13.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Dosage Form, 2017–2031
13.5.1. Tablet
13.5.2. Solution
13.5.3. Others
13.6. Market Value Forecast, by Distribution Channel, 2017–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Application
13.8.3. By Route of Administration
13.8.4. By Dosage Form
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Cardiotonic Agents Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2017–2031
14.2.1. Digitalis Glycosides
14.2.2. Phosphodiesterase Inhibitors
14.2.3. Cardioprotectants
14.2.4. Sympathomimetic Agents
14.2.5. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Cardiac Surgical Procedures
14.3.2. Atrial Fibrillation
14.3.3. Heart Failure
14.3.4. Pulmonary Hypertension
14.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Dosage Form, 2017–2031
14.5.1. Tablet
14.5.2. Solution
14.5.3. Others
14.6. Market Value Forecast, by Distribution Channel, 2017–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Application
14.8.3. By Route of Administration
14.8.4. By Dosage Form
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Cardiotonic Agents Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2017–2031
15.2.1. Digitalis Glycosides
15.2.2. Phosphodiesterase Inhibitors
15.2.3. Cardioprotectants
15.2.4. Sympathomimetic Agents
15.2.5. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Cardiac Surgical Procedures
15.3.2. Atrial Fibrillation
15.3.3. Heart Failure
15.3.4. Pulmonary Hypertension
15.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Dosage Form, 2017–2031
15.5.1. Tablet
15.5.2. Solution
15.5.3. Others
15.6. Market Value Forecast, by Distribution Channel, 2017–2031
15.6.1. Hospital Pharmacies
15.6.2. Retail Pharmacies
15.6.3. Online Pharmacies
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Application
15.8.3. By Route of Administration
15.8.4. By Dosage Form
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Cardiotonic Agents Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Type, 2017–2031
16.2.1. Digitalis Glycosides
16.2.2. Phosphodiesterase Inhibitors
16.2.3. Cardioprotectants
16.2.4. Sympathomimetic Agents
16.2.5. Others
16.3. Market Value Forecast, by Application, 2017–2031
16.3.1. Cardiac Surgical Procedures
16.3.2. Atrial Fibrillation
16.3.3. Heart Failure
16.3.4. Pulmonary Hypertension
16.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)
16.4. Market Value Forecast, by Route of Administration, 2017–2031
16.4.1. Oral
16.4.2. Parenteral
16.5. Market Value Forecast, by Dosage Form, 2017–2031
16.5.1. Tablet
16.5.2. Solution
16.5.3. Others
16.6. Market Value Forecast, by Distribution Channel, 2017–2031
16.6.1. Hospital Pharmacies
16.6.2. Retail Pharmacies
16.6.3. Online Pharmacies
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Application
16.8.3. By Route of Administration
16.8.4. By Dosage Form
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Amneal Pharmaceuticals LLC
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Pfizer Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Hikma Pharmaceuticals PLC
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Fresenius Kabi
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Midas Pharma GmbH
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Sanofi
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Aurobindo Pharma Limited
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. SimSon Pharma Limited
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Other Players
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
List of Tables
Table 01: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 05: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031
Table 07: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 08: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 10: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 11: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 13: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 14: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 15: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 16: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 18: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 20: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 23: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 26: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 28: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 30: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 31: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 33: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 34: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 35: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
List of Figures
Figure 01: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Cardiotonic Agents Market Value Share, by Drug Type, 2022
Figure 03: Cardiotonic Agents Market Value Share, by Application, 2022
Figure 04: Cardiotonic Agents Market Value Share, by Route of Administration, 2022
Figure 05: Cardiotonic Agents Market Value Share, by Dosage Form, 2022
Figure 06: Cardiotonic Agents Market Value Share, by Distribution Channel, 2022
Figure 07: Cardiotonic Agents Market Value Share, by Radiotracer Type, 2022
Figure 08: Global Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 09: Global Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 10: Global Cardiotonic Agents Market Revenue (US$ Mn), by Digitalis Glycosides, 2017–2031
Figure 11: Global Cardiotonic Agents Market Revenue (US$ Mn), by Phosphodiesterase Inhibitors, 2017–2031
Figure 12: Global Cardiotonic Agents Market Revenue (US$ Mn), by Cardioprotectants, 2017–2031
Figure 13: Global Cardiotonic Agents Market Revenue (US$ Mn), by Sympathomimetic Agents, 2017–2031
Figure 14: Global Cardiotonic Agents Market Revenue (US$ Mn), by Others, 2017–2031
Figure 15: Global Cardiotonic Agents Market Value Share Analysis, by Application 2022 and 2031
Figure 16: Global Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 17: Global Cardiotonic Agents Market Revenue (US$ Mn), by Cardiac Surgical Procedures, 2017–2031
Figure 18: Global Cardiotonic Agents Market Revenue (US$ Mn), by Atrial Fibrillation, 2017–2031
Figure 19: Global Cardiotonic Agents Market Revenue (US$ Mn), by Heart Failure, 2017–2031
Figure 20: Global Cardiotonic Agents Market Revenue (US$ Mn), by Pulmonary Hypertension, 2017–2031
Figure 21: Global Cardiotonic Agents Market Revenue (US$ Mn), by Others (Atrial Flutter, Cardiogenic Shock, etc.), 2017–2031
Figure 21: Global Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 23: Global Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 24: Global Cardiotonic Agents Market Revenue (US$ Mn), by Oral, 2017–2031
Figure 25: Global Cardiotonic Agents Market Revenue (US$ Mn), by Parenteral, 2017–2031
Figure 26: Global Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 27: Global Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 28: Global Cardiotonic Agents Market Revenue (US$ Mn), by Tablet, 2017–2031
Figure 29: Global Cardiotonic Agents Market Revenue (US$ Mn), by Solution, 2017–2031
Figure 30: Global Cardiotonic Agents Market Value Share Analysis, by Others 2022 and 2031
Figure 31: Global Cardiotonic Agents Market Value Share Analysis, by Distribution Channel 2022 and 2031
Figure 32: Global Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Figure 33: Global Cardiotonic Agents Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 34: Global Cardiotonic Agents Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 35: Global Cardiotonic Agents Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 36: Global Cardiotonic Agents Market Value Share Analysis, by Country, 2022 and 2031
Figure 37: Global Cardiotonic Agents Market Attractiveness Analysis, by Country, 2023–2031
Figure 38: North America Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 39: North America Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 40: North America Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 41: North America Cardiotonic Agents Market Value Share Analysis, by Application 2022 and 2031
Figure 42: North America Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 43: North America Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 44: North America Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 45: North America Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 46: North America Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 47: North America Cardiotonic Agents Market Value Share Analysis, by Distribution Channel 2022 and 2031
Figure 48: North America Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Figure 49: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 50: Europe Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Europe Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 52: Europe Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 53: Europe Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 54: Europe Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Europe Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 56: Europe Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 57: Europe Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 58: Europe Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 59: Europe Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 60: Europe Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 61: Europe Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Figure 62: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 63: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 64: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 65: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 66: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 67: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031
Figure 68: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 69: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 70: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 71: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 72: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 73: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 74: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Figure 75: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 76: Latin America Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 77: Latin America Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 78: Latin America Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 79: Latin America Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 80: Latin America Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031
Figure 81: Latin America Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 82: Latin America Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 83: Latin America Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 84: Latin America Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 85: Latin America Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 86: Latin America Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 87: Latin America Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Figure 88: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 89: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 90: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 91: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031
Figure 92: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031
Figure 93: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031
Figure 94: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031
Figure 95: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031
Figure 96: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031
Figure 97: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031
Figure 98: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031
Figure 99: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 100: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cardiotonic Agents Market
*86 figures and 60 tables includes